The Food and Drug Administration today withdrew approval for Makena and its generics, citing a confirmatory study that did not verify clinical benefit. Makena had been approved under the FDA’s accelerated approval pathway to reduce the risk of preterm birth in women pregnant with one baby who have a history of spontaneous preterm birth. Makena and its generics cannot lawfully be distributed in interstate commerce, effective immediately. FDA is aware that some products have already been distributed, so health care providers should talk to their patients, if applicable.

Related News Articles

Headline
The Joint Commission July 29 announced an initiative to address “gaps” in how children’s hospitals are accredited and certified. The program will remove or…
Headline
The AHA July 24 announced it is collaborating with health care technology leader Epic to help hospitals adopt tools that support the early detection and…
Headline
A Health Affairs study on the decline of obstetric services in rural and urban hospitals nationwide from 2010-2022 found that seven states had at least 25% of…
Headline
The Food and Drug Administration has issued early alerts for certain Spectrum infusion pumps from Baxter and Abiomed Automated Impella Controllers. The agency…
Headline
The latest video in the AHA’s series “Medicaid: Real Lives, Real Care” features Melissa Fannon-Wisner, DNP, nurse educator and nurse practitioner at Valley…
Headline
Kevin McEwan, DNP, R.N., chief nursing officer at Madison Memorial Hospital, shares how Medicaid provides vital behavioral health and maternal and child care…